.jpg)
Lithuania: Emerging Life Science Leader
Lithuania is an EU member state boasting the largest economy among its neighboring Baltic states.
According to Labiotech1, Lithuania’s life science sector is growing at an approximate rate of 20-25% per year, with 90% of the country’s life science products and services being exported internationally.
Lithuania’s prestigious and state-subsidized university system fosters a highly educated workforce and promotes collaboration between academia and industry to advance scientific research and drive innovation.
Reference:
1. Bancroft D. What Is Lithuania's Role in European Biotech? Labiotech.eu Web site. https://labiotech.eu/policy-legal-finance/biotech-lithuania/. Accessed May 22,2019.
Flexible, Modern Facilities
Our state-of-the-art facilities include 25 R&D labs as well as a cGMP manufacturing plant with both single-use and stainless steel systems for upstream and downstream process development, formulation and fill-finish of microbial and mammalian cell culture-based products. Our flexible, integrated infrastructure enables us to develop, formulate and manufacture clients’ proteins and antibodies as well as the corresponding aseptic drug products at a range of scales.
We are continuously investing in the expansion of our facilities to better serve our global clients. To that end, we are increasing our microbial cGMP manufacturing capacity by adding a new production facility with 30-300-3,000 L working volume bioreactor train.
We are a 20-minute drive from Vilnius International Airport, which can be easily accessed via multiple daily flights from many European cities and hubs, as well as other global locations.
